Oxford Technology 2 VCT plc : Half-year Report Oxford

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
196
Oxford Technology 2 VCT plc : Half-year Report

Oxford Technology 2 Venture Capital Trust Plc

Unaudited Half-Yearly Report

For the period

1 March 2017 to 31 August 2017

Financial Headlines

  6 Months Ended 31 August 2017 Year Ended 28 February 2017  
Net Assets at Period End   £2.64m £2.53m
Net Asset Value per Share   38.9p 37.2p
Cumulative Dividend per Share   13.0p 13.0p
Total NAV Return per Share   51.9p 50.2p
Share Price at Period End   30.0p 20.0p
Earnings per Share 1.7p 9.0p  

                                                                                          

Company Number: 3928569 Registered Address: The Magdalen Centre, Oxford Science Park, Oxford OX4 4GA

Statement on behalf of the Board  

I am pleased to present the unaudited results for the six month period ended 31 August 2017, which has been a busy time for your Company.

Results The Company's net asset value (NAV) per share has increased from 37.2p at 28 February 2017 by 1.7p to 38.9p at 31 August 2017, mainly due to a slight increase in the adjusted final sale price of OC Robotics and a value uplift following a recent investment round in ImmunBiology Limited ("Immbio"). 

Sale of OC Robotics (OCR) and resultant Return of Funds to shareholders The investment in OCR was sold to GE Aircraft Engine Services Ltd on 8 June 2017, yielding an immediate payment of £1,356k to OT2 with a further £327k being held in escrow for 24 months against normal business warranties and an estimated £98k of excess cash to be released shortly. In line with OT2's normal practice, 50% of both the amount in escrow and the estimated excess cash have been recognised in the NAV. OT2 originally invested £125k in 2001 when the company was a start-up, and then made additional investments over the years taking the total investment to £311k by the date of the most recent annual accounts to 28 February 2017, when it was valued at £1,535k. So far, the investment has therefore returned a 5 fold uplift vs cost.

With significant cash proceeds available, the Board offered shareholders the opportunity to sell 30% of their holding back to the Company via a Tender Offer, together with further shares should other shareholders not take up their Basic Entitlement.  On 6 September 2017, just after the period end, the Company completed the Tender Offer, with a total of 1,461,034 Ordinary Shares being tendered. As this was less than the 2,037,877 shares that the Company was authorised to buy back all the Ordinary Shares tendered by shareholders were re-purchased, for £460k.

The Circular also indicated that a dividend would be paid to shareholders still on the register after the completion of the Tender Offer. This is still the intention, and as not all the funds earmarked for the Tender Offer were required for that purpose, the Directors expect to declare a slightly higher dividend of at least 8p per share, with a payment by 7 December 2017.

Portfolio Review The 8 unlisted companies within the portfolio continue to develop, and where required and permitted under VCT rules your Company continues to invest to support that development.  During the period, an additional investment of £30k was made into Immbio: The company attended our recent AGM and its presentation (along with that given by Arecor, another OT2 investee) can be found on our website. The recent investment in Immbio was in a new class of share with a significant preference.  This has resulted in an uplift in its valuation of nearly £100k.

Select Technology, a photocopier (or more generally Multi Function Device, or MFD) software company, is now the largest holding in your Company's portfolio (over a third of the total investment value). The company is profitable and continues to grow, despite the strategic decision to reduce dependency on one particular supplier, which is expected to increase business resilience.  Taking these developments into account, we have reverted to a valuation methodology based on a sales multiple to more appropriately reflect the prospects of the business, although the impact of this is small during the half year period. 

The Directors along with the Investment Advisor continue to take an active interest in the remaining companies within the portfolio, both to support their management teams to achieve company development, but also to prepare companies for realisation at the appropriate time. It should however be noted that approaches do occur at other times, and the ability of the Directors and Investment Advisor to be able to provide support when such approaches occur is essential for maximising value. This was demonstrated in the recent realisation of OCR.

Liquidity Given the illiquidity of the current portfolio, the level of dividend declared above is set at a level such that the Company retains sufficient cash to ensure it can continue to operate for the foreseeable future, and yet remain VCT qualifying. Some portfolio companies will require further financing, and as always, these will be considered on a case by case basis.

VCT qualifying status The Board has procedures in place to ensure that the Company continues to comply with the conditions laid down by HMRC for maintaining approval as a VCT.

Presentation of half-yearly report In order to reduce the length of this report, we have omitted details of the Company's objectives and investment strategy, its Advisers and Registrar and how to buy and sell shares in the Company. These details are all included in the Annual Reports, which together with previous half-yearly reports, are available for viewing on the Oxford Technology website.

Outlook Your Directors continue to monitor changes to VCT legislation, and their potential impact on both the VCT and its investee companies. The recent publication of the Patient Capital Review makes many recommendations regarding investment into early stage high growth companies. It is expected that this may drive additional changes to tax efficient investment schemes. Your Directors do not expect that this will have any material impact on the current portfolios or on current investors as the VCT is fully invested. Likewise, whilst the impact of Brexit remains unclear, your Directors do not expect its eventual outcome to have a material impact on portfolio valuations.

In July, the Board announced that it was aware that due to recent realisations, the VCT is becoming sub economic with unavoidable overheads on a small asset base. The VCT has limited ability to increase the asset base on its own, and a number of options to deal with this are under consideration. I can confirm that discussions continue regarding these options, and am hopeful that we can make a further announcement in the not too distant future.  Once a proposal that the Board considers to be in the best interests of existing shareholders is sufficiently advanced, shareholders will be invited to approve any new arrangements. However, there can be no certainty that any of these discussions will lead to a concrete proposal, either at this time or in the future.

The Directors' view remains that the portfolio, while concentrated, still holds significant potential over the medium term but is not without risk. The ongoing strategy is to seek to crystallise value from the portfolio and distribute cash to shareholders when the opportunity arises.

Finally I would like to take this opportunity to thank shareholders, many of whom we were able to welcome to our AGM in July, for their continued support.

Richard Roth Chairman 20 October 2017

Investment Portfolio as at 31 August 2017

Company Description Net Cost of investment £'000 Carrying value at 31/8/17 £'000 Change in value for the 6 month period £'000 % Equity held OT2 % Equity held All OT % of fund investment value
Select Technology Photocopier interfaces 132 346 5 7.4 58.6 34.1
ImmBio Novel vaccines 255 189 127 2.0 16.2 18.7
               
Plasma Antennas   Solid state antennas 188 142 13 5.6 48.9 14.0
Arecor Protein stabilisation 89 121 - 1.2 11.3 11.9
               
Orthogem Bone graft material 342 100 - 5.4 20.2 9.9
               
Insense Active would healing dressings 204 52 - 2.0 6.8 5.1
Inaplex Data transformation software 138 37 - 21.5 34.8 3.6
Oxis Energy Rechargeable batteries 540 27 - 0.2 0.5 2.7
Total Investments   1,889 1,014   145     100%
Other Net Assets     1,626          
  Net Assets       2,640        

Responsibility Statement of the Directors in respect of the half-yearly report

We confirm that to the best of our knowledge:

  • the half-yearly financial statements have been prepared in accordance with the statement "Interim Financial Reporting" issued by the Financial Reporting Council;
  • the half-yearly report includes a fair review of the information required by the Financial Services Authority Disclosure and Transparency Rules, being:
  • an indication of the important events that have occurred during the first six months of the financial year and their impact on the condensed set of financial statements.  
  • a description of the principal risks and uncertainties for the remaining six months of the year.  
  • a description of related party transactions that have taken place in the first six months of the current financial year that may have materially affected the financial position or performance of the Company during that period and any changes in the related party transactions described in the last annual report that could do so.

On behalf of the Board:

Richard Roth Chairman 20 October 2017 Income Statement

  Six months to 31 Aug 2017 Six months to 31 Aug 2016 Year to 28 February 2017
  Revenue Capital Total Revenue Capital Total Revenue Capital Total
  £'000 £'000 £'000 £'000 £'000 £'000 £'000 £'000 £'000
Gain on disposal of fixed asset investments - 33 33 - - - - - -
Unrealised gain on valuation of fixed asset investments - 115 115 - 20 20 - 653 653
Investment income - - - - - - 27 - 27
Investment management fees (3)  (9) (12) (2) (8) (10) (5) (14) (19)
Other expenses (24) - (24) (23) - (23) (45) - (45)
Return on ordinary activities before tax (27) 139 112 (25) 12 (13) (23) 639 616
Taxation on ordinary activities - - - - - - - - -
Return on ordinary activities after tax (27) 139 112 (25) 12 (13) (23) 639 616
Earnings per share - basic and diluted (0.4)p 2.1p 1.7p (0.4)p 0.2p (0.2)p (0.4)p 9.4p 9.0p
  • The 'Total' column of this statement is the profit and loss account of the Company; the supplementary Revenue return and Capital return columns have been prepared under guidance published by the Association of Investment Companies.
  • All revenue and capital items in the above statement derive from continuing operations.
  • The accompanying notes are an integral part of the half-yearly report.
  • The Company has only one class of business and derives its income from investments made in shares and securities and from bank and money market funds.

The Company has no recognised gains or losses other than the results for the period as set out above. Accordingly a Statement of Comprehensive Income is not required.

Balance Sheet

  As at 31 Aug 2017 As at 31 Aug 2016 As at 28 February 2017
  £'000 £'000 £'000 £'000 £'000 £'000
Fixed asset investments   (At fair value through profit and loss)   1,014   1,672   2,405
Current assets:            
Debtors 227     14     2  
Creditors: Amounts falling due within one year (18)    (23)     (25)  
Cash at Bank 1,417   245   146  
Net current assets   1,626   236   123
Creditors: Amount falling due in more than one year   -   (9)   -
Net assets   2,640   1,899   2,528
Called up equity share capital   679   679   679
Share premium   376   376   376
Unrealised capital reserve   (874)   (398)   235
Profit and Loss account reserve   2,459   1,242   1,238
Total equity shareholders' funds   2,640   1,899   2,528
Net asset value per share   38.9p   28.0p   37.2p

Statement of Changes in Equity

  Share Capital £'000 Share Premium £'000 Unrealised Capital Reserve £'000 Profit & Loss   Reserve £'000 Total £'000
           
As at 1 March 2016 679 376 (418) 1,275 1,912
Revenue return on ordinary activities after tax - - - (25) (25)
Expenses charged to capital - - - (8) (8)
Current period gains on fair value of investments - - 20 - 20
Balance as at 31 August 2016 679 376 (398) 1,242 1,899
           
As at 1 March 2016 679 376 (418) 1,275 1,912
Revenue return on ordinary activities after tax - - - (23) (23)
Expenses charged to capital - - - (14) (14)
Current period gains on fair value of investments - - 653 - 653
Balance as at 28 February 2017 679 376 235 1,238 2,528
           
As at 1 March 2017 679 376 235 1,238 2,528
Revenue return on ordinary activities after tax - - - (27) (27)
Expenses charged to capital - - - (9) (9)
Current period gains on fair value of investments - - 115 - 115
Current period gains on disposal - - - 33 33
Prior years' gains now realised - - (1,224) 1,224 -
Balance as at 31 August 2017 679 376 (874) 2,459 2,640

Statement of Cash Flows

  Six months to 31 Aug 2017 Six months to 31 Aug 2016 Year to 28 February 2017
  £'000 £'000 £'000
Cash flows from operating activities      
Return on ordinary activities before tax 112 (13) 616
Adjustments for:      
(Increase)/Decrease in debtors (225) 7 19
Decrease in creditors (7) (12) (19)
Gain on disposal of fixed asset investments (33) - -
Gain on valuation of fixed asset investments (115) (20) (653)
Movement in investment debtors and creditors 213 - -
Outflow from operating activities (55) (38) (37)
Cash flows from investing activities      
Purchase of fixed asset investments (30) (50) (150)
Sale of fixed asset investments 1,356 - -
Total cash flows from investing activities 1,326 (50) (150)
       
Cash flows from financing activities      
       
Dividends paid - - -
Total cash flows from financing activities - - -
       
Increase/(decrease) in cash and cash equivalents 1,271 (88) (187)
       
Opening cash and cash equivalents 146 333 333
       
Closing cash and cash equivalents 1,417 245 146

  

Notes to the Half-Yearly Report

1.         Basis of preparation The unaudited half-yearly results which cover the six months to 31 August 2017 have been prepared in accordance with the Financial Reporting Council's (FRC) Financial Reporting Standard 104 Interim Financial Reporting ('FRS 104') and the Statement of Recommended Practice (SORP) for Investment Companies re-issued by the Association of Investment Companies in November 2014. Details of the accounting policies and valuation methodologies are included in the Annual Report.

2.         Publication of non-statutory accounts The unaudited half-yearly results for the six months ended 31 August 2017 do not constitute statutory accounts within the meaning of Section 415 of the Companies Act 2006. The comparative figures for the year ended 28 February 2017 have been extracted from the audited financial statements for that year, which have been delivered to the Registrar of Companies. The independent auditor's report on those financial statements, in accordance with chapter 3, part 16 of the Companies Act 2006, was unqualified. This half-yearly report has not been reviewed by the Company's auditor.

3.         Earnings per share The calculation of earnings per share for the period is based on the return attributable to shareholders divided by the weighted average number of shares in issue during the period. There are no potentially dilutive capital instruments in issue and, therefore, no diluted returns per share figures are relevant.

4.         Net asset value per share The net asset value per share is based on the net assets at the period end divided by the number of shares in issue at that date (6,792,923 in each case).

5.         Principal risks and uncertainties The Company's assets consist of equity and fixed interest investments, cash and liquid resources. Its principal risks are therefore market risk, credit risk and liquidity risk. Other risks faced by the Company include economic, loss of approval as a Venture Capital Trust, investment and strategic, regulatory, reputational, operational and financial risks. These risks, and the way in which they are managed, are described in more detail in the Company's Annual Report and Accounts for the year ended 28 February 2017. The Company's principal risks and uncertainties have not changed materially since the date of that report.

6.         Related party transactions OT2 Managers Ltd, a wholly owned subsidiary, provides investment management services to the Company for a fee of 1% of net assets per annum.

7.   Events after the Balance Sheet Date On 6 September 2017, the Company bought back, and cancelled, 1,461,034 shares at 31.5p (representing 21.5% of the issued share capital), under the Tender Offer Circular dated 26 July 2017. The number of shares now in issue is 5,331,889 Ordinary Shares.

8.          Copies of this statement are available from Oxford Technology Management, The Magdalen Centre, Oxford Science Park, Oxford OX4 4GA and on the Company's website - www.oxfordtechnology.com /vct2.

Board Directors : Richard Roth, Alex Starling, Robin Goodfellow, and David Livesley

Investment Manager : OT2 Managers Ltd with services contracted to Oxford Technology Management Ltd

Website: www.oxfordtechnology.com/vct2

Enquiries: Lucius Cary, Oxford Technology Management 01865 784466

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Webull Faces Class Action: Deadline Looms Dec 2026

Updated Category News Views 48

Sinking Shares: The Webull Saga Unfolds Shady business practices can really make a stock take a nosedive, and that's what's happening with Webull Corporation, trading under NASDAQ:BULL. The alarm bells started ringing when the truth about their operations and ties to China came out. Turns out, what looked like a stable American fintech platform had its roots digging deep...

Continue Reading
Globe Life Faces Investor Scrutiny Over Leadership

Updated Category News Views 54

Shareholders Put Globe Life Under the Microscope There's something cooking at Globe Life Inc., and it isn't a savory stew of shareholder satisfaction. See, when an investor rights firm like Halper Sadeh LLC starts poking around, suspecting a breach of fiduciary duty by the folks at the top, you know there's some smoke. Questions are looming over whether some brass at...

Continue Reading
New Navy Contract Boosts X-Bow's Defense Portfolio

Updated Category News Views 92

Will X-Bow's CHAOS contract shake up defense? Ever get the feeling you're watching a scrappy upstart quietly transform an industry? That's the buzz around X-Bow Systems Inc (X-Bow®) as they announce a partnership with CoAspire for the U.S. Navy's CHAOS program. This ain't just another contract; it's a cornerstone moment for them. So, what's fueling the excitement?...

Continue Reading
GoldMining Kicks Off 6,000-Metre Drilling at São Jorge

Updated Category News Views 7

GoldMining's Bold Move in Brazil GoldMining Inc. is shaking things up at their São Jorge project in Brazil, launching a rigorous 6,000-metre infill diamond drill campaign. This ain't just a slapdash project—they're truly digging in with three diamond core rigs already churning away at the depths of São Jorge's mineral bounty. Drilling for Confidence Why all the...

Continue Reading
Latham & Harvey Boost Fund Formation With AI Tech

Updated Category News Views 164

AI Joins Forces with Legal Expertise Latham & Watkins LLP and Harvey are teaming up to revolutionize how fund formation gets done. They're jumping into the AI waters with both feet, aiming to make the fund documentation process less of a nightmare and more of a breeze for lawyers. The idea isn't just to cut down on the grunt work, but to let attorneys zero in on what's...

Continue Reading
Clip Expands Horizons with Pulpos Acquisition, New Board Member

Updated Category News Views 0

Clip's Strategic Move with Pulpos Clip just laid down a serious marker in the digital payment world by snagging Pulpos, a firm that’s got its claws deep into AI-driven business management software. This move isn't just some fancy headline. It's a real, grounded step in expanding Clip's ecosystem to bolster the backbone of Mexico's economy: small and medium-sized...

Continue Reading
Gilded Dragonfly Gallery: A Jewel in Brunswick's Crown

Updated Category News Views 120

There's something remarkable happening in Brunswick, Maryland. This small town's stirring to life with a splash of creativity, and it's just gotten a little brighter with the grand opening of the Gilded Dragonfly Gallery. This isn't just another art gallery popping up; it's a statement of transformation, from quiet exurbia to a thriving arts destination. Jayme Marshall:...

Continue Reading
Ferrovial's EUR 600M Scrip Dividend: What's Brewing?

Updated Category News Views 77

Understanding Ferrovial's Latest Financial Maneuver Alright, investors, listen up—Ferrovial's just tossed a hefty EUR 600 million scrip dividend onto the table, giving shareholders the choice between cash or shares. Now, if you've been around the block, this sort of move can mean a few things, and it's best not to treat it like coins rattling in a collection plate. This...

Continue Reading
Jiahui's Bold Leap into Global Cell Therapy Market

Updated Category News Views 66

Jiahui's International Cell Therapy Center: A New Era Jiahui International Hospital is shaking up the healthcare scene with its fresh International Cell Therapy Center, diving headfirst into the cutting-edge world of CAR-T treatments. It's not every day you see this kind of bold move, especially from a player aiming to extend their reach both in China and abroad. Let's...

Continue Reading
Scams vs Identity Theft: Trauma's Dark Impact Revealed

Updated Category News Views 56

Facing the Dark Reality of Scams and Identity Theft Imagine facing a bleak financial horizon because of scams and identity theft, but the weight on your soul ain't about just numbers. That's what the Identity Theft Resource Center's 2026 Consumer Impact Report brings to light. We're talking about massive mental and emotional whirlwinds, way beyond mere dollars and cents....

Continue Reading

Top 5 Most Recently Viewed Articles

Unity Software's Strategic Options Activity and Market Insights

Updated Category News Views 136

Unity Software's Strategic Options Activity Recent activity among large financial entities indicates a bullish sentiment towards Unity Software (U). An analysis of the options trading history for the company has unveiled 30 unusual trades that warrant attention. Understanding Options Activity Upon closer inspection, it appears that 60% of the traders are betting on the...

Continue Reading
Magna International's Strategic Senior Notes Offer Explained

Updated Category News Views 358

Magna International Initiates Senior Notes Offerings Magna International Inc. (NYSE: MGA; TSX: MG) has announced a significant step in its financing strategy through the offering of two series of senior notes. This includes Euro-denominated senior notes and U.S. dollar-denominated senior notes. The company is looking to leverage these offerings to bolster its financial...

Continue Reading
Silex Technology Launches Innovative SoM for Edge-AI Use

Updated Category News Views 248

Silex Technology Introduces Cutting-Edge SoM for Industries At the recent Embedded World 2025 event, Silex Technology made headlines with the unveiling of the AMC Edge System-on-Module (SoM), designated EP-200Q. This state-of-the-art module excels in providing high-performance Wi-Fi 7 connectivity tailored for industrial AI applications. Overview of the AMC Edge...

Continue Reading
Wolters Kluwer's Recent Share Buyback Highlights Key Moves

Updated Category News Views 177

Wolters Kluwer's Recent Share Buyback Moves Wolters Kluwer, a prominent global leader in professional information solutions, software, and services, is executing strategic buyback initiatives aimed at bolstering shareholder value. As part of these efforts, the company executed a significant repurchase of 76,100 of its ordinary shares, investing €7.4 million. This...

Continue Reading
PepGen Inc. Legal Actions: Protecting Investor Rights Today

Updated Category News Views 111

Understanding Recent Legal Challenges Faced by PepGen Inc. PepGen Inc., a clinical-stage biotechnology company, is caught up in a class action lawsuit that addresses crucial issues impacting its investor base. This case centers around allegations involving their lead product candidate, PGN-EDO51, aimed at treating Duchenne muscular dystrophy (DMD). Investors who acquired...

Continue Reading